|
|||||
|
|
Multicenter validation of the value of BASFI and BASDAI in Chinese ankylosing spondylitis and undifferentiated spondyloarthropathy patients |
|
| Authors: | Zhiming Lin Jieruo Gu Peigen He Jiesheng Gao Xiaoxia Zuo Zhizhong Ye Fengmin Shao Feng Zhan Jinying Lin Li Li Yanlin Wei Manlong Xu Zetao Liao Qu Lin |
| Affiliation: | 1. Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-sen University, Tianhe Road No 600, 510630, Guangzhou, China 2. Department of Rheumatology, Tongji Hospital, Tongji Medical College, Central China University of Science and Technology, Hubei, China 3. Department of Rheumatology, Xiangya Second Affiliated Hospital, Central South University, Hunan, China 4. Department of Rheumatology, Xiangya First Affiliated Hospital, Central South University, Hunan, China 5. Shenzhen Rheumatology Institute of Guangdong Medical College, Shenzhen, China 6. Department of Rheumatology, Henan Provincial People??s Hospital, Zhengzhou, China 7. Department of Rheumatology, Hainan Provincial People??s Hospital, Guangzhou, China 8. Department of Rheumatology, Guangxi Zhuangzu Autonomous Region People??s Hospital, Nanning, China |
| Abstract: | The objectives of this study were to evaluate the reliability of Bath ankylosing spondylitis functional index (BASFI) and Bath ankylosing spondylitis disease activity index (BASDAI) in Chinese ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA) patients. 664 AS patients by the revised New York criteria for AS and 252 USpA patients by the European Spondyloarthropathy Study Group criteria were enrolled. BASDAI and BASFI questionnaires were translated into Chinese. Participants were required to fill in BASFI and BASDAI questionnaires again after 24?h. Moreover, BASDAI and BASFI were compared in AS patients receiving Enbrel or infliximab before and after treatment. For AS group, BASDAI ICC: 0.9502 (95% CI: 0.9330?C0.9502, ???=?0.9702), BASFI ICC: 0.9587 (95% CI: 0.9521?C0.9645, ???=?0.9789). For USpA group, BASDAI ICC: 0.9530 (95% CI: 0.9402?C0.9632, ???=?0.9760), BASFI ICC: 0.9900 (95% CI: 0.9871?C0.9922, ???=?0.9950). In the AS group, disease duration, occipital wall distance, modified Schober test, chest expansion, ESR, and CRP showed significant correlation with BASDAI and BASFI (all P?P?P?P? |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |